Last update 29 Dec 2024
VR-506
Last update 29 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with VR-506A Randomised Double-blind, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of VR506 From a New Dry Powder Inhaler in Subjects With Severe Persistent Asthma Requiring Oral Corticosteroid Therapy.
A randomised, double-blind, placebo controlled, parallel group, study to evaluate the efficacy and safety of VR506 inhalation powder from a new dry powder inhaler in adolescent and adult subjects with asthma. - Clinical study to evaluate the use of a new VR506 inhaler to treat Asthma
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of VR506 Inhaled From a New Inhaler in Adolescent and Adult Subjects With Asthma
100 Clinical Results associated with VR-506
Login to view more data
100 Translational Medicine associated with VR-506
Login to view more data
100 Patents (Medical) associated with VR-506
Login to view more data
100 Deals associated with VR-506
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Persistent asthma | Phase 3 | US | 01 Oct 2012 | |
| Persistent asthma | Phase 3 | BG | 01 Oct 2012 | |
| Persistent asthma | Phase 3 | DE | 01 Oct 2012 | |
| Persistent asthma | Phase 3 | HU | 01 Oct 2012 | |
| Persistent asthma | Phase 3 | PL | 01 Oct 2012 | |
| Persistent asthma | Phase 3 | RO | 01 Oct 2012 | |
| Persistent asthma | Phase 3 | UA | 01 Oct 2012 | |
| Persistent asthma | Phase 3 | GB | 01 Oct 2012 | |
| Asthma | Phase 3 | US | 01 Oct 2011 | |
| Asthma | Phase 3 | PH | 01 Oct 2011 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2/3 | 197 | (Dose 1 VR506 50 mcg) | fnhsqjzpce(kcjugnurtf) = czfujtzffm lejhsqfqic (vemoomaurj, pcxkrhzqcf - lliufskfvi) View more | - | 21 Apr 2020 | ||
(Dose 2 VR506 250 mcg) | fnhsqjzpce(kcjugnurtf) = xhldkoeyos lejhsqfqic (vemoomaurj, txlfxukute - zymxomxudq) View more | ||||||
Phase 2/3 | 374 | Placebo | dhfwyqvywu(bwfhoagtae) = orxfurzuat jpfxlzvpqz (drkpitlwse, wpiqofynzk - otihqyrbvc) View more | - | 21 Apr 2020 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free